APA (7th ed.) Citation

A, K., R, P., J, V., Y, C., VB, S., R, K., & M, M. (2026). A Real-World Phase IV Superiority Trial and Cost-Effectiveness Analysis of the Addition of Low-Dose Nivolumab to Triple Metronomic Chemotherapy Compared to the Paclitaxel Carboplatin Regimen in Recurrent or Metastatic Head and Neck Cancer Patients. Head & neck, 48(3), 765. https://doi.org/10.1002/hed.70077

Chicago Style (17th ed.) Citation

A, Khadela, Parikh R, Vaghela J, Chauhan Y, Shah VB, Kothari R, and Merja M. "A Real-World Phase IV Superiority Trial and Cost-Effectiveness Analysis of the Addition of Low-Dose Nivolumab to Triple Metronomic Chemotherapy Compared to the Paclitaxel Carboplatin Regimen in Recurrent or Metastatic Head and Neck Cancer Patients." Head & Neck 48, no. 3 (2026): 765. https://doi.org/10.1002/hed.70077.

MLA (9th ed.) Citation

A, Khadela, et al. "A Real-World Phase IV Superiority Trial and Cost-Effectiveness Analysis of the Addition of Low-Dose Nivolumab to Triple Metronomic Chemotherapy Compared to the Paclitaxel Carboplatin Regimen in Recurrent or Metastatic Head and Neck Cancer Patients." Head & Neck, vol. 48, no. 3, 2026, p. 765, https://doi.org/10.1002/hed.70077.